FY2030 Earnings Forecast for Evotec Issued By HC Wainwright

Evotec AG (NASDAQ:EVO) – Equities research analysts at HC Wainwright issued their FY2030 earnings per share estimates for Evotec in a research note issued to investors on Wednesday, April 15th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of $0.48 per share for the year. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.41) per share.

Evotec (NASDAQ:EVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.05 earnings per share for the quarter. The company had revenue of $297.02 million for the quarter. Evotec had a negative return on equity of 12.40% and a negative net margin of 13.13%.

A number of other research analysts also recently issued reports on the company. Berenberg Bank initiated coverage on Evotec in a report on Tuesday, February 3rd. They set a “buy” rating on the stock. Wall Street Zen upgraded Evotec from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Evotec in a research report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $7.00.

Evotec Price Performance

Evotec stock opened at $3.22 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.07 and a quick ratio of 1.99. The business’s fifty day simple moving average is $2.94 and its two-hundred day simple moving average is $3.29. Evotec has a 12 month low of $2.31 and a 12 month high of $4.80.

Institutional Trading of Evotec

Hedge funds have recently bought and sold shares of the company. Marshall Wace LLP purchased a new stake in Evotec during the fourth quarter valued at $40,000. Valeo Financial Advisors LLC purchased a new stake in Evotec during the second quarter valued at $43,000. BNP Paribas Financial Markets increased its position in Evotec by 62.2% during the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after acquiring an additional 4,600 shares during the last quarter. Thrivent Financial for Lutherans purchased a new stake in Evotec during the third quarter valued at $53,000. Finally, Bank of America Corp DE increased its position in Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after acquiring an additional 9,289 shares during the last quarter. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.